Long-Term Statin Use Is Associated With Reduced Rates of Adverse Events in Patients With Newly Diagnosed Atrial...

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Uncertainty surrounds the effectiveness of statins in preventing cardiovascular events in atrial fibrillation (AF) patients.
• This study investigates the potential benefits of statin therapy for individuals diagnosed with AF.

Purpose of the Study:

• To evaluate the impact of statin use on cardiovascular outcomes in patients with atrial fibrillation.
• To determine if statin therapy improves survival and reduces adverse events in this population.

Main Methods:

• Analysis of a large cohort of 288,958 patients with newly diagnosed AF (2012-2020).
• Comparison of outcomes between statin users and non-users, including composite endpoints, all-cause mortality, and major adverse cardiovascular events (MACE).
• Stratification of analysis by CHA2DS2-VASc scores to assess effectiveness across different risk levels.

Main Results:

• Statin users showed significantly lower risks of composite endpoints (ischemic stroke, hemorrhagic stroke, TIA) compared to non-users (aHR, 0.91).
• Statin use was associated with a substantial reduction in all-cause mortality (aHR, 0.33) and MACE (aHR, 0.64).
• Benefits of statins on composite endpoints were most pronounced in patients with CHA2DS2-VASc scores of 0-3, while mortality and MACE reductions were observed across all risk scores.

Conclusions:

• Statin therapy is associated with reduced risks of stroke, all-cause mortality, and major adverse cardiovascular events in patients with newly diagnosed atrial fibrillation.
• The findings support the use of statins as a beneficial intervention for managing cardiovascular risk in AF patients.
• Statin effectiveness in reducing mortality and MACE is consistent across varying CHA2DS2-VASc risk scores in AF patients.